Celgene Corp
Business Description
Celgene Corp is a biopharmaceutical company that focuses on developing innovative therapeutics for the treatment of cancer and other serious medical conditions. The company was founded in 1986 and is headquartered in Summit, New Jersey, USA. It is widely known for its pioneering work in multiple myeloma, a rare type of cancer that affects plasma cells in the bone marrow.
Celgene*s mission is to improve the lives of patients and their families by developing and commercializing therapies that target a wide range of diseases, including cancer, inflammatory conditions, and autoimmune disorders. The company*s expertise lies in drug discovery, preclinical research, clinical development, and commercialization.
Celgene has a diverse pipeline of products, which includes multiple myeloma, leukemia, lymphoma, solid tumors, and inflammatory conditions such as psoriasis and Crohn*s disease. The company*s flagship product is Revlimid (lenalidomide), a first-in-class oral therapy for the treatment of multiple myeloma and myelodysplastic syndromes.
In addition to Revlimid, Celgene also markets Pomalyst (pomalidomide) for multiple myeloma and Dexamethasone for inflammatory conditions. The company*s portfolio also includes Otezla (apremilast), a first-in-class oral therapy for the treatment of psoriasis and psoriatic arthritis.
Celgene is committed to advancing the science and understanding of diseases through research collaborations and partnerships with academic institutions, industry organizations, and patient advocacy groups. The company has a strong corporate responsibility program, which includes initiatives to support patient access to its drugs, advance employee health and wellness, and promote environmental sustainability.
Overall, Celgene is a biopharmaceutical company that is dedicated to using innovative science to improve the lives of patients affected by serious medical conditions. The company*s focus on drug discovery, clinical development, and commercialization has led to the development of groundbreaking therapies, including several first-in-class medicines that have transformed the treatment landscape for cancer and other diseases.
|